Germany’s Federal Ministry of Education and Research (BMBF) will invest €39 million to fight drug-resident superbugs after teaming up with Boston non-profit CARB-X.
Over four years, the funding will be used in the early development of antibiotics, vaccines and diagnostics to combat drug-resistant bacteria.
BMBF will also provide an additional €1 million in direct support to a consortium of the German Centre for Infection Research (DZIF), the Federal Institute for Vaccines and Biomedicines (PEI) and the Federal Institute for Drugs and Medical Devices (BfArM), which is joining the CARB-X Global Accelerator Network, a network of 10 accelerators around the world to support CARB-X funded projects.
Germany joins CARB-X funders and global leaders in the fight against superbugs: the Biomedical Advanced Research and Development Authority (BARDA), part of the US Department of Health and Human Services‘ Office of the Assistant Secretary for Preparedness and Response (ASPR), the Wellcome Trust, a global charity based in the UK working to improve health globally, the UK Government’s Global Antimicrobial Resistance Innovation Fund (UK GAMRIF), the Bill & Melinda Gates Foundation, and with in-kind support, the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH).
BMBF will sit on CARB-X’s governing board, the Joint Oversight Committee, which establishes funding strategies and makes investment decisions based on recommendations from the CARB-X Advisory Board.
With the BMBF partnership, CARB-X now has up to €480 million to help accelerate antibacterial innovation around the world.
Launched in 2016, CARB-X funds and supports the world’s largest, most diverse and rapidly growing portfolio of products under development to address serious life-threatening drug resistant bacteria. There are currently 35 projects in the portfolio in 6 countries.